We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Collection of CTCs Improves Prostate Cancer Diagnosis

By LabMedica International staff writers
Posted on 16 Sep 2019
A recent paper described the benefits of circulating tumor cell (CTC) analysis for improving the diagnosis of aggressive prostate cancer beyond currently used PSA (prostate specific antigen) measurement, biopsy and/or MRI imagery.

PSA testing can result in unnecessary biopsies and over-diagnosis with consequent over-treatment. More...
Tissue biopsy is an invasive procedure, associated with significant risk of complications. More accurate non- or minimum-invasive diagnostic approaches are required to avoid unnecessary prostate biopsy and over-diagnosis.

Towards this end, investigators at Queen Mary University of London (United Kingdom) evaluated the potential of using circulating tumor cell analysis for prostate cancer diagnosis, particularly in predicting the presence of clinically significant prostate tumors in patients prior to biopsy.

The investigators used the ANGLE plc (Surrey, United Kingdom) Parsortix system to capture and analyze CTCs from 98 pre-biopsy and 155 newly diagnosed prostate cancer patients.

The Parsortix liquid biopsy process requires a blood sample - typically 10 milliliters in an EDTA vacutainer tube. As no pre-processing is required, the tube is simply attached to the Parsortix instrument. A Parsortix filtration cassette is inserted into the instrument and the system is primed for use. The instrument automatically passes the blood through the filtration cassette, and CTCs are caught in the cassette due to their larger size and lower compressibility as compared to other blood components.

Once trapped in the cassette, CTCs may be automatically stained with selected antibodies, which enables their identification and characterization. In addition, CTCs may be enumerated by placing the filtration cassette under a fluorescent microscope. Alternatively, cells may be eluted from the cassette and recovered in buffer solution for genomic analysis.

Results obtained with the Parsortix system indicated that the appearance of CTCs in pre-biopsy blood samples was indicative of the presence of aggressive prostate cancer. When the CTC tests results were combined with those of the current PSA test, the presence of aggressive prostate cancer in subsequent biopsies was predicted with accuracy of over 90%, better than any previously reported biomarkers.

Senior author Dr. Yong-Jie Lu, professor of molecular oncology at Queen Mary University of London said, "The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and over treatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for better selection of patients to undergo the biopsy procedure. Testing for circulating tumor cells is efficient, non-invasive, and potentially accurate, and we have now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer."

The study was published in the August 7, 2019, online edition of the Journal of Urology.

Related Links:
Queen Mary University of London
ANGLE plc


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: The partnership between OGT and QIAGEN unlocks a complete sample to report workflow for SureSeq NGS panels (Photo courtesy of OGT)

Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation

In clinical research, next-generation sequencing (NGS) panels provide essential insights for genetic analysis, but many laboratories face challenges in transforming raw sequencing data into clinically... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.